A clinical case of reverse left ventricular remodeling in patient with pathogenic TTN mutation. Case report
- Authors: Nasonova S.N.1, Meshkov A.N.1,2, Zhirov I.V.1, Osmolovskaya Y.F.1, Shoshina A.A.1, Gagloev A.V.1, Dzhumaniiazova I.H.3, Zelenova E.A.3, Erema V.V.3, Gusakova M.S.3, Ivanov M.V.3, Terekhov M.V.3, Kashtanova D.A.3, Nekrasova A.I.3, Mitrofanov S.I.3, Shingaliev A.S.3, Yudin V.S.3, Keskinov A.A.3, Gomyranova N.V.1, Chubykina U.V.1, Ezhov M.V.1, Tereshchenko S.N.1, Yudin S.M.3, Boytsov S.A.1
-
Affiliations:
- Chazov National Medical Research Center of Cardiology
- National Research Center for Therapy and Preventive Medicine
- Centre for Strategic Planning and Management of Biomedical Health Risks
- Issue: Vol 96, No 9 (2024): Кардиология
- Pages: 901-908
- Section: Clinical notes
- URL: https://journals.rcsi.science/0040-3660/article/view/267776
- DOI: https://doi.org/10.26442/00403660.2024.09.202852
- ID: 267776
Cite item
Full Text
Abstract
Dilated cardiomyopathy (DCM) is a leading cause of heart failure, sudden cardiac death, and heart transplantation in young patients. The causes of DCM are varied and include genetic factors and metabolic, infectious, toxic and others factors. Today it is known that germline mutations in more than 98 genes can be associated with the occurrence of DCM. However, the penetrance of these genes often depends on a combination of factors, including modifiable ones, i.e. those that change under the influence of the environment. About 20–25% of genetically determined forms of DCM are due to mutations in the titin gene (TTN). Titin is the largest protein in the body, which is an important component of the sarcomer. Although titin is the largest protein in the human body, its role in the physiology of heart and disease is not yet fully understood. However, a mutation in the TTN gene may later represent a potential therapeutic target for genetic and acquired cardiomyopathy. Thus, the analysis of clinical cases of cardiomyopathy in patients with identified mutations in the TTN gene is of great scientific interest. The article presents a clinical case of manifestation of DCM in patient with a revealed pathogenic variant of mutation in the gene TTN and reverse left ventricular remodeling of the against the background of optimal therapy of heart failure in a subsequent outpatient observation.
Full Text
##article.viewOnOriginalSite##About the authors
Svetlana N. Nasonova
Chazov National Medical Research Center of Cardiology
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0002-0920-7417
кандидат медицинских наук, старший научный сотрудник отделения заболеваний миокарда и сердечной недостаточности
Russian Federation, MoscowAleksei N. Meshkov
Chazov National Medical Research Center of Cardiology; National Research Center for Therapy and Preventive Medicine
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0001-5989-6233
доктор медицинских наук, помощник ген. директора по научной и клинической работе НМИЦК им. акад. Е.И. Чазова, рук. Института персонализированной терапии и профилактики ФГБОУ «НМИЦ терапии и профилактической медицины»
Russian Federation, Moscow; MoscowIgor V. Zhirov
Chazov National Medical Research Center of Cardiology
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0002-4066-2661
доктор медицинских наук, ведущий научный сотрудник отделения заболеваний миокарда и сердечной недостаточности
Russian Federation, MoscowYulia F. Osmolovskaya
Chazov National Medical Research Center of Cardiology
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0002-7827-2618
кандидат медицинских наук, зав. 8-м кардиологическим отделением, научный сотрудник отд. заболеваний миокарда и сердечной недостаточности
Russian Federation, MoscowAnastasiia A. Shoshina
Chazov National Medical Research Center of Cardiology
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0002-9519-7373
аспирант отделения заболеваний миокарда и сердечной недостаточности
Russian Federation, MoscowAlan V. Gagloev
Chazov National Medical Research Center of Cardiology
Email: dr.nasonova@mail.ru
ORCID iD: 0009-0009-0976-9442
врач-ординатор отд. заболеваний миокарда и сердечной недостаточности
Russian Federation, MoscowIrina H. Dzhumaniiazova
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0001-5167-2112
аналитик отд. медицинской геномики
Russian Federation, MoscowElena A. Zelenova
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
аналитик отделения медицинской геномики
Russian Federation, MoscowVeronika V. Erema
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0003-0547-3280
кандидат медицинских наук, аналитик II категории отделения медицинской геномики
Russian Federation, MoscowMariia S. Gusakova
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0002-0036-9241
аналитик отделения медицинской геномики
Russian Federation, MoscowMikhail V. Ivanov
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
вед. аналитик отделения медицинской геномики
Russian Federation, MoscowMikhail V. Terekhov
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
ORCID iD: 0009-0006-4549-7470
аналитик отделения медицинской геномики
Russian Federation, MoscowDaria A. Kashtanova
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0001-8977-4384
кандидат медицинских наук, вед. аналитик отделения медицинской геномики
Russian Federation, MoscowAlexsandra I. Nekrasova
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0002-7951-2003
аналитик I категории отделения медицинской геномики
Russian Federation, MoscowSergey I. Mitrofanov
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0003-0358-0568
нач. отделения системной биологии и биоинформатики
Russian Federation, MoscowAndrey S. Shingaliev
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
ORCID iD: 0009-0002-1488-2721
аналитик отделения медицинской геномики
Russian Federation, MoscowVladimir S. Yudin
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0002-9199-6258
кандидат биологических наук, директор Института синтетической биологии и генной инженерии
Russian Federation, MoscowAnton A. Keskinov
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0001-7378-983X
кандидат медицинских наук, кандидат экономических наук, зам. ген. директора
Russian Federation, MoscowNataliya V. Gomyranova
Chazov National Medical Research Center of Cardiology
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0003-4500-0904
доктор биол. наук, зав. отделением клинической лабораторной диагностики
Russian Federation, MoscowUliana V. Chubykina
Chazov National Medical Research Center of Cardiology
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0003-2760-2792
кандидат медицинских наук, мл. научный сотрудник лаборатории нарушений липидного обмена
Russian Federation, MoscowMarat V. Ezhov
Chazov National Medical Research Center of Cardiology
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0002-1518-6552
доктор медицинских наук, главный научный сотрудник лаб. нарушений липидного обмена
Russian Federation, MoscowSergey N. Tereshchenko
Chazov National Medical Research Center of Cardiology
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0001-9234-6129
доктор медицинских наук, профессор, руководитель отделения заболеваний миокарда и сердечной недостаточности
Russian Federation, MoscowSergey M. Yudin
Centre for Strategic Planning and Management of Biomedical Health Risks
Author for correspondence.
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0002-7942-8004
доктор медицинских наук, генеральный директор
Russian Federation, MoscowSergey A. Boytsov
Chazov National Medical Research Center of Cardiology
Email: dr.nasonova@mail.ru
ORCID iD: 0000-0001-6998-8406
академик РАН доктор медицинских наук, профессор, генеральный директор
Russian Federation, MoscowReferences
- Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850-8. doi: 10.1093/eurheartj/ehv727
- Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015;36(18):1123-35a. doi: 10.1093/eurheartj/ehu301
- McNally EM, Mestroni L. Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. Circ Res. 2017;121(7):731-48. doi: 10.1161/CIRCRESAHA.116.309396
- Ware JS, Amor-Salamanca A, Tayal U, et al. Genetic Etiology for Alcohol-Induced Cardiac Toxicity. J Am Coll Cardiol. 2018;71(20):2293-302. doi: 10.1016/j.jacc.2018.03.462
- Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic Variants Associated with Cancer Therapy-Induced Cardiomyopathy. Circulation. 2019;140(1):31-41. doi: 10.1161/CIRCULATIONAHA.118.037934
- Ware JS, Li J, Mazaika E, et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med. 2016;374(3):233-41. doi: 10.1056/NEJMoa1505517
- LeWinter MM, Granzier HL. Titin is a major human disease gene. Circulation. 2013;127(8):938-44. doi: 10.1161/CIRCULATIONAHA.112.139717
- Shyr C, Tarailo-Graovac M, Gottlieb M. FLAGS, frequently mutated genes in public exomes. BMC Med Genomics. 2014;64. doi: 10.1186/s12920-014-0064-y
- Golbus JR, Puckelwartz MJ, Fahrenbach JP, et al. Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet. 2012;5(4):391-9. doi: 10.1161/CIRCGENETICS.112.962928
- Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619-28. doi: 10.1056/NEJMoa1110186
- Roberts AM, Ware JS, Herman DS, et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med. 2015;7(270):270ra6. doi: 10.1126/scitranslmed.3010134
- Shyr C, Tarailo-Graovac M, Gottlieb M, et al. FLAGS, frequently mutated genes in public exomes. BMC Med Genomics. 2014;7:64. doi: 10.1186/s12920-014-0064-y
- Clinical Genome Resource. Cardiovascular CDWG – ClinGen. Available at: https://clinicalgenome.org/working-groups/clinical-domain/cardiovascular. Accessed: 12.11.2023.
- Kim S, Scheffler K, Halpern AL, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods. 2018;15(8):591-4. doi: 10.1038/s41592-018-0051-x
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24. doi: 10.1038/gim.2015.30
- LeWinter MM, Wu Y, Labeit S, Granzier H. Cardiac titin: structure, functions and role in disease. Clin Chim Acta. 2007;375(1-2):1-9. doi: 10.1016/j.cca.2006.06.035
- Ware JS, Cook SA. Role of titin in cardiomyopathy: from DNA variants to patient stratification. Nat Rev Cardiol. 2018;15(4):241-52. doi: 10.1038/nrcardio.2017.190
- Tharp CA, Haywood ME, Sbaizero O, et al. The Giant Protein Titin’s Role in Cardiomyopathy: Genetic, Transcriptional, and Post-translational Modifications of TTN and Their Contribution to Cardiac Disease. Front Physiol. 2019;10:1436. doi: 10.3389/fphys.2019.01436
- Tobita T, Nomura S, Fujita T, et al. Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep. 2018;8(1):1998. doi: 10.1038/s41598-018-20114-9
- Verdonschot JAJ, Hazebroek MR, Wang P, et al. Clinical Phenotype and Genotype Associations with Improvement in Left Ventricular Function in Dilated Cardiomyopathy. Circ Heart Fail. 2018;11(11):e005220. doi: 10.1161/CIRCHEARTFAILURE.118.005220
- Vissing CR, Rasmussen TB, Dybro AM, et al. Dilated cardiomyopathy caused by truncating titin variants: long-term outcomes, arrhythmias, response to treatment and sex differences. J Med Genet. 2021;58(12):832-41. doi: 10.1136/jmedgenet-2020-107178
- Akhtar MM, Lorenzini M, Cicerchia M, et al. Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circ Heart Fail. 2020;13(10):e006832. doi: 10.1161/CIRCHEARTFAILURE.119.006832
- Jansweijer JA, Nieuwhof K, Russo F, et al. Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. Eur J Heart Fail. 2017;19(4):512-21. doi: 10.1002/ejhf.673
- Escobar-Lopez L, Ochoa JP, Mirelis JG, et al. Association of Genetic Variants with Outcomes in Patients with Nonischemic Dilated Cardiomyopathy. J Am Coll Cardiol. 2021;78(17):1682-99. doi: 10.1016/j.jacc.2021.08.039
- Tayal U, Newsome S, Buchan R, et al. Phenotype and Clinical Outcomes of Titin Cardiomyopathy. J Am Coll Cardiol. 2017;70(18):2264-74. doi: 10.1016/j.jacc.2017.08.063
- Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375(13):1221-30. doi: 10.1056/NEJMoa1608029
- Gigli M, Merlo M, Graw SL, et al. Genetic Risk of Arrhythmic Phenotypes in Patients with Dilated Cardiomyopathy. J Am Coll Cardiol. 2019;74(11):1480-90. doi: 10.1016/j.jacc.2019.06.072
- Corden B, Jarman J, Whiffin N, et al. Association of Titin-Truncating Genetic Variants with Life-threatening Cardiac Arrhythmias in Patients with Dilated Cardiomyopathy and Implanted Defibrillators. JAMA Netw Open. 2019;2(6):e196520. doi: 10.1001/jamanetworkopen.2019.6520
- Ahlberg G, Refsgaard L, Lundegaard PR, et al. Rare truncating variants in the sarcomeric protein titin associate with familial and early-onset atrial fibrillation. Nat Commun. 2018;9(1):4316. doi: 10.1038/s41467-018-06618-y
- Choi SH, Weng LC, Roselli C, et al. Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. JAMA. 2018;320(22):2354-64. doi: 10.1001/jama.2018.18179
- Körtl T, Schach C, Sossalla S. How arrhythmias weaken the ventricle: an often underestimated vicious cycle. Herz. 2023;48(2):115-22. doi: 10.1007/s00059-022-05158-y
- Huttner IG, Wang LW, Santiago CF, et al. A-Band Titin Truncation in Zebrafish Causes Dilated Cardiomyopathy and Hemodynamic Stress Intolerance. Circ Genom Precis Med. 2018;11(8):e002135. doi: 10.1161/CIRCGEN.118.002135
- Pedretti S, Vargiu S, Baroni M, et al. Complexity of scar and ventricular arrhythmias in dilated cardiomyopathy of any etiology: Long-term data from the SCARFEAR (Cardiovascular Magnetic Resonance Predictors of Appropriate Implantable Cardioverter-Defibrillator Therapy Delivery) Registry. Clin Cardiol. 2018;41(4):494-501. doi: 10.1002/clc.22911
- Verdonschot JAJ, Hazebroek MR, Derks KWJ, et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur Heart J. 2018;39(10):864-73. doi: 10.1093/eurheartj/ehx808
- Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43(8):716-99. doi: 10.1093/eurheartj/ehab892
Supplementary files
